AbbVie's VRAYLAR Now Publicly Reimbursed In Ontario On Its Provincial Formulary As A General Benefit; Listing Will Be Effective On October 31, 2024
Portfolio Pulse from Benzinga Newsdesk
AbbVie announced that its drug VRAYLAR will be publicly reimbursed in Ontario as a General Benefit starting October 31, 2024. This move aims to improve access to mental illness medication in Canada, following similar listings in Québec and by federal programs.
October 29, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AbbVie's VRAYLAR will be publicly reimbursed in Ontario, effective October 31, 2024, enhancing access to mental illness medication. This follows similar listings in Québec and federal programs.
The public reimbursement of VRAYLAR in Ontario is a significant development for AbbVie, as it expands the drug's accessibility in a major Canadian province. This could lead to increased sales and market penetration in Canada, positively impacting AbbVie's revenue from VRAYLAR. The news follows a successful agreement with the pan-Canadian Pharmaceutical Alliance, indicating strong support for the drug's adoption.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90